This article is more than 5 years old. Information may no longer be current.

Eight important updates for Triple-Negative Breast Cancer Awareness Day

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Today is Triple-Negative Breast Cancer Awareness Day.

Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases.

The aggressive subtype is so named because the estrogen, progestin and HER2 receptors are not expressed. Most approved therapies target these receptors, making triple-negative disease difficult to treat and leading to poor prognosis.

Five-year survival rates are 91% for those with localized disease, 65% for those with regional disease and 11% for those with distant disease.

Triple-negative breast cancer accounts for 15% of all cases.

Source: Adobe

This breast cancer subtype is more common among women aged younger than 40 years, black women and those with BRCA1 mutations.

In conjunction with Triple-Negative Breast Cancer Awareness Day, Healio and HemOnc Today present the following updates in research and treatment.

• The addition of pembrolizumab (Keytruda, Merck) to first-line chemotherapy significantly extended PFS among patients with metastatic triple-negative breast cancer whose tumors express PD-L1, according to results of the randomized phase 3 KEYNOTE-355 study. Read more.
• The addition of the AKT inhibitor capivasertib (AZD5363, AstraZeneca) to first-line paclitaxel extended PFS and OS among a cohort of women with previously untreated, metastatic triple-negative breast cancer. Read more.
• Detection of circulating tumor DNA after neoadjuvant chemotherapy appeared to independently predict disease recurrence among women with early-stage triple-negative breast cancer. Read more.
• The addition of pembrolizumab to neoadjuvant chemotherapy and as adjuvant therapy increased pathologic complete response among patients with high-risk triple-negative breast cancer, including those with stage III disease and those with lymph node involvement. Read more.
• The addition of atezolizumab (Tecentriq, Genentech) to neoadjuvant chemotherapy failed to improve pathologic complete response rate for patients with triple-negative breast cancer. Read more.
• In this commentary, Gregory A. Vidal, MD, PhD, and colleagues assert that investigations into new targets, combination therapies, other novel treatment strategies and biomarkers make this an “exciting time” for triple-negative breast cancer. Read more.
• Pembrolizumab plus radiotherapy appeared safe and demonstrated encouraging clinical activity among a small cohort of women with poor-prognosis, metastatic triple-negative breast cancer. Read more.
• Chaitali Nangia, MD, MBBS, co-director of medical oncology at Chan Soon-Shiong Institute for Medicine, provided an update on the QUILT-3.067 study to evaluate the safety and efficacy of metronomic combination therapy among patients with triple-negative breast cancer who progressed on or after standard-of-care chemotherapy. Read more.